SEARCH

SEARCH BY CITATION

References

  • Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. & Drew, R. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673680.
  • Buxbaum, J. (1986) Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. Journal of Clinical Investigation, 78, 798806.
  • Clark, R.J., Katzmann, J.A., Abraham, R.S., Lymph, J.F., Kyle, R.A. & Bradwell, A.R. (2001) Detection of monoclonal free light chains by nephelometry: normal ranges and relative sensitivity. Clinical Chemistry, 47, a27.
  • Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Journal of Clinical Oncology, 19, 33503356.
  • Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 29002902.
  • Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1991) Response rates and survival in primary systemic amyloidosis. Blood, 77, 257262.
  • Gertz, M.A., Lacy, M.Q. & Dispenzieri, A. (2000) Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplantation, 25, 465470.
  • Gillmore, J.D., Apperley, J.F., Pepys, M.B. & Hawkins, P.N. (1999) High dose chemotherapy for systemic AL amyloidosis. Kidney International, 55, 2103.
  • Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Rahman, V., Stangou, A.J., Pepys, M.B. & Hawkins, P.N. (2000) Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. Quarterly Journal of Medicine, 93, 269275.
  • Gillmore, J.D., Lovat, L.B., Persey, M.R., Pepys, M.B. & Hawkins, P.N. (2001a) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet, 358, 2429.
  • Gillmore, J.D., Stangou, A.J., Tennent, G.A., Booth, D.R., O'Grady, J., Rela, M., Heaton, N.D., Wall, C.A., Keogh, J.A. & Hawkins, P.N. (2001b) Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation, 71, 986992.
  • Hawkins, P.N. (1997) The diagnosis, natural history and treatment of amyloidosis. The Goulstonian Lecture 1995. Journal of the Royal College of Physicians London, 31, 552560.
  • Hawkins, P.N., Lavender, J.P. & Pepys, M.B. (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. New England Journal of Medicine, 323, 508513.
  • Katzmann, J.A., Clark, R.J., Abraham, R.S., Bryant, S., Lymp, J.F., Bradwell, A.R. & Kyle, R.A. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48, 14371444.
  • Keren, D.F. (1999) Procedures for the evaluation of monoclonal immunoglobulins. Archives of Pathology and Laboratory Medicine, 123, 126132.
  • Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 4559.
  • Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A. & Lacy, M.Q. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 12021207.
  • Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Pepys, M.B. & Hawkins, P.N. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 17861791.
  • Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A., Caillot, D., Hermine, O., Attal, M., Hamidou, M., Nedellec, G., Ferrant, A., Audhuy, B., Bataille, R., Milpied, N. & Harousseau, J.L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766769.
  • Raje, N., Powles, R., Kulkarni, S., Milan, S., Middleton, G., Singhal, S., Mehta, J., Millar, B., Viner, C., Raymond, J., Treleaven, J., Cunningham, D. & Gore, M. (1997) A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology, 97, 153160.
  • Rydh, A., Suhr, O., Hietala, S.-O., Åhlström, K.R., Pepys, M.B. & Hawkins, P.N. (1998) Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. European Journal of Nuclear Medicine, 25, 709713.
  • Samson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882885.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Dember, L.M., Finn, K., Falk, R.H., Berk, J., Quillen, K. & Skinner, M. (2001) An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 28, 637642.
  • Schey, S.A., Kazmi, M., Ireland, R. & Lakhani, A. (1998) The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma. European Journal of Haematology, 61, 306310.
  • Tan, S.Y. & Pepys, M.B. (1994) Amyloidosis. Histopathology, 25, 403414.
  • Tan, S.Y., Irish, A., Winearls, C.G., Brown, E.A., Gower, P.E., Clutterbuck, E.J., Madhoo, S., Lavender, J.P., Pepys, M.B. & Hawkins, P.N. (1996) Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney International, 50, 282289.